All verification complete. Final report:

# Conference Participant Output: ci-phase8-task85-html-ppt-visual-review - visual_single_object

## Boundary Check

- Read-only verification pass; no files edited; runner report path not written — this text is the report for the runner to persist.
- Current live files re-opened fresh in headless Chromium at 1440×900 via `file://`; no reliance on prior screenshots or cached DOM. Deck hashes confirmed unchanged since my second pass (`9d0767…/b89cf8…/fd2d47…`, mtimes ~12:36–12:37), so no new edit round landed since then — the `_label_lines` wrap regression I reported in pass 2 is still present in the candidates under review.
- No Task 8.6 full-deck aesthetic review performed; Codex remains final acceptance authority.

## Independent Work Product

### Prior blockers — verified CLOSED (direct browser evidence)

1. **C `c-stats` sample sizes — CLOSED.** Live DOM on slide 11 shows `740 例` (度普利尤单抗·CHRONOS·NCT02260986), `445 例` (ADvocate2·NCT04178967), `941 例` (nemolizumab·NCT03985943), `331 例` (ADvantage·NCT05149313), each badge `已公开`; all four analysis-set rows read 「登记记录未单独公开分析集」 badge `未公开`. Screenshot confirms visual rendering. Matches locked input (`threshold_value` 740/445/941/331 例, `reported_value`).
2. **No raw `>=` on C audience slides — CLOSED.** Programmatic scan of all 18 C slides (notes excluded): zero occurrences of `>=` or `<=`. Sampled rows render `EASI ≥ 16 分`, `IGA ≥ 2 分` uniformly on c-inclusion / c-endpoints / c-identity.
3. **Paren-name label truncation — CLOSED.** `a-efficacy` renders 「乐德奇拜单抗」/「（Rademikibart / SIM0718）」 and 「611」/「（SSGJ-611）」 complete with closing parens; `a-matrix` page 1 shows all 10 labels complete including the full two-line 乐德奇拜单抗（Rademikibart / SIM0718）. Measured pairwise overlap test over all a-matrix label boxes: **zero overlaps, zero clipping** (previous ICP-332/司普奇拜单抗 collision resolved).

### Repaired-surface regression checks — passed

- **A matrix coverage**: a-matrix 10 paired + a-matrix-2 9 paired = 19, with 6 unpaired products named as 不画点 (Eblasakimab, SHR-1819, APG777, Bermekimab, Rocatinlimab, Tezepelumab). No silent coverage truncation.
- **C c-endpoints**: all four cards retain drug + trial + NCT + endpoint/threshold + 第16周 (IGA ≥ 2 分 ×3; ADvantage EASI ≥ 75 %改善）.
- **B b-matrix**: y-axis title 「治疗期间不良事件（%）」 fully rendered vertically (measured w=25, h=197, no clip), x-axis title complete, exactly one real bubble (circle r=26, APPLY), APPOINT shown as 不适用 with reason, no composite score.
- **Page numbers**: exactly once on every inspected slide (c-stats `11 / 18`, c-endpoints `9 / 18`, a-efficacy `7 / 20`, a-efficacy-3 `9 / 20`, a-efficacy-4 `10 / 20`, a-efficacy-5 `11 / 20`, a-matrix `13 / 20`, a-matrix-2 `14 / 20`, b-matrix `7 / 24`, b-efficacy `4 / 24`).

### Remaining deterministic defect (carried over from pass 2, still unfixed)

4. **Mid-word label wraps with dangling 1–2-char tails on bar charts and one bubble.** Live SVG evidence on current files:
   - `b-efficacy`: `APPOINT-PNH` renders as two text nodes `APPOINT-PN` / `H` (screenshot visually confirms the dangling "H").
   - `a-efficacy-3`: `Eblasakima` / `b`, `Rocatinlim` / `ab`; `a-efficacy-4`: `Amlitelima` / `b`, `Tezepeluma` / `b`, `Rezpegalde` / `sleukin`; `a-efficacy-5`: `Rocatinlim` / `ab`, `Amlitelima` / `b`.
   - `a-matrix` bubble: `Rezpegaldesleukin` tspans are `Rezpegaldesl` / `eukin` (mid-word, though both halves are substantial).
   - Root cause unchanged: `_label_lines` (`charts.py:15-28`) splits paren-less roman labels by hard character count (bars `max_chars=10`, bubbles `max_chars=12`) with no hyphen/word-boundary branch; the old `-` split was dropped in the fix round.
   - Identity completeness: no characters are lost — concatenated lines reconstruct the full name, so this is broken typography, not truncation. But `APPOINT-PN / H` and `Eblasakima / b` on required pages (B efficacy; A efficacy continuations) read as rendering bugs. The SVG `aria-label` carries only the chart title (e.g. 「疗效（续2）」), not per-product identity, so visible labels are the only identity carrier and must be clean. **My standing recommendation: this blocks 8.6 entry** — one small `_label_lines` fix (split at `-` when both parts ≥3 chars; else raise bar `max_chars` to 12 or hyphenate the break; never emit a 1-char tail line).

Minor (8.6-level, non-blocking): on b-efficacy the tall 92.2 bar's value label crowds the top-right legend (「治疗组 92.2」 visually adjacent); 「EASI ≥ 75 %改善」 spacing persists on c-endpoints/c-identity.

## Evidence And Assumptions

- Direct browser evidence: live DOM text dumps (c-stats, c-endpoints, b-matrix, b-efficacy, all a-efficacy pages, both a-matrix pages); SVG `<text>`/`<tspan>` enumeration proving the dangling tails; pairwise bounding-box overlap test on a-matrix (zero overlaps); B-matrix axis-title geometry (w/h); circle count; page-number node counts per slide; screenshots of c-stats, b-efficacy, a-efficacy-3, a-matrix.
- Source corroboration: `charts.py:15-28,100-103,294-298`, `c.py:85,96-99`; locked-input `planned_or_actual_sample_size` values.
- Inference `[INFERENCE]`: deck files unchanged since pass 2 (identical SHA-256), so the pass-2 source reading of `_label_lines` still describes the running code; no fix round occurred between passes.
- Assumption: cover/toc/ending without page numbers remains intended master behavior.

## Risks, Gaps, And Verification Needs

- The dangling-tail wrap pattern (finding 4) may also exist on chart-bearing slides I did not re-enumerate this pass; after the `_label_lines` fix, re-dump SVG text on every chart slide (a-efficacy×5, a-matrix×2, b-efficacy, b-matrix) before 8.6.
- WebKit not re-verified (covered by worker contract tests).
- Bounded decision for Codex: finding 4 is the only remaining deterministic defect from my passes. Block 8.6 until the one-function fix lands (my recommendation), or accept it as the first mandatory 8.6 item — if accepted, require the SVG-text re-dump above as the gate.

## Recommended Next Step

1. Apply the `_label_lines` fix in `charts.py` (hyphen-boundary split for paren-less roman labels; no 1-char tails), re-render the three decks, re-run `tests/html_ppt/`.
2. Re-verify by SVG-text dump that `APPOINT-PNH`, `Eblasakimab`, `Rocatinlimab`, `Amlitelimab`, `Tezepelumab`, `Rezpegaldesleukin` render without mid-word dangling tails.
3. With that single change: both original blockers are verified closed, all named regression surfaces pass, and no other deterministic blocker exists — Task 8.6 can begin as the exhaustive polish pass.
